Navigation
Open Access
Review

Renal transplantation in amyloidosis and MIDD

Lauren Stern1,Andrea Havasi1,*
1
Renal Section, Boston University School of Medicine, 650 Albany Str, 5th floor, Boston, MA, 02118, USA
DOI: 10.2741/724 Volume 7 Issue 1, pp.171-180
Published: 01 January 2015
*Corresponding Author(s):  
Andrea Havasi
E-mail:  
ahavasi@bu.edu
Abstract

Amyloidosis and monoclonal immunoglobulin deposition disease, though rare entities, can wreak havoc on the architecture and functioning of the kidneys. These diseases have a predilection to cause severe renal dysfunction leading to end stage renal disease (ESRD). In recent years, the available treatments for these diseases have expanded and afflicted patients are living longer, but with advanced kidney disease. Because of the complex nature of the pathophysiology and treatment of these diseases, it can be very challenging for a clinician to determine whether or not it is appropriate to refer an affected individual for kidney transplantation.

Key words

Renal transplant, Amyloidosis, TTR, AL amyloid, AA amyloid, Familial Amyloidosis, Review

Share and Cite
Lauren Stern, Andrea Havasi. Renal transplantation in amyloidosis and MIDD. Frontiers in Bioscience-Elite. 2015. 7(1); 171-180.